

# Diabetes during pregnancy

# Diabetes during pregnancy

- Diabetes is a common complication of pregnancy.
- The prevalence of diabetes is about 15% in the pregnant women.
- The more and more attention was paid to diabetes during pregnancy.

# Classification

- Pregestational or overt: be diagnosed before pregnancy.
- Gestational diabetes Mellitus(GDM) : be diagnosed during pregnancy.
- GDM is more common than the overt diabetes.

# Gestational diabetes mellitus

- Definition: any degree carbohydrate intolerance with onset or first recognition during pregnancy.
- GDM is more common than the overt diabetes.
- The GDM account for more than 90% of the whole diabetes during pregnancy.
- GDM could contain some pregestational diabetes.

# The impacts between pregnancy and diabetes

- The pregnancy and diabetes can impact each other.
- On one hand, the pregnancy can aggravate the diabetes.
- On the other hand, diabetes can exert adverse effects on the pregnant effects.

# The impact of pregnancy on diabetes

- The insulin sensitivity is lowered during pregnancy.
- We should adjust the dosage of insulin according to the placenta status.

# The adverse effects of diabetes

- The overt diabetes has more adverse effects than the GDM.
- The adverse effects on the fetus
- The adverse effects on the pregnant women.

# Pathophysiology –placenta(1)

- The placenta can secrete a variety of hormones.
- These hormones include estrogen, progesterone, cortisol, human placental lactogen, human chorionic gonadotropin, etc.
- The hormones produced by placenta antagonize the effects of insulin.
- It is estimated that the insulin sensitivity will be decreased by 40% in the 3rd trimester.



# Pathophysiology-placenta

- The decreased insulin sensitivity is the key for the mechanism of GDM.
- For GDM, there are no placental hormones after delivery of placenta, so the insulin sensitivity and the blood glucose levels would be restored to the normal.

# Complications of pregnancy in pre-existing DM

## Maternal:

- Increase insulin requirement
- Hypoglycemia
- Infection
- Ketoacidosis
- Deterioration in retinopathy
- Increased proteinuria+edema
- Miscarriage
- Polyhydramnio
- Shoulder dystocia
- Preeclampsia
- Increased caesarean rate

## Fetal:

- Congenital abnormalities
- Increased neonatal and perinatal mortality
- Macrosomia
- Late stillbirth
- Neonatal hypoglycemia
- Polycythemia
- jaundice



# Screening

- The challenge of glucose tolerance must be done for most cases with GDM.

# The fasting glucose level

- Normal: <5.1 mmol/l
- Suspected pregestational diabetes: >7.0mmol/l
- Suspected GDM: 5.1-7.0 mmol/l



# GDM Screening

- All women should be screened for GDM between 24-28 weeks
- Women with multiple risk factors should be screened in the first trimester



# Risk Factors: for first trimester screening

- $\geq 35$  yrs
- BMI  $\geq 30$
- Previous diagnosis of GDM
- Delivery of a macrosomic baby
- Member of a high-risk population
- Acanthosis nigricans
- Corticosteroid use
- PCOS

# The diagnosis criteria

---

Glucose measure	Glucose level threshold
Fasting plasma glucose	5.1mmol/l
1h plasam glucose	10.0mmol/l
2h plasma glucose	8.5mmol/l

---

\*One or more of these values from a 75-g OGTT must be equaled or exceeded for the diagnosis of GDM.

---

# Antepartum Management

- There is a consensus that once diabetes is diagnosed, the treatment should be recommended for diabetes during pregnancy.
- The goals of treatment are to prevent macrosomia, avoid ketosis, and detect pregnancy complications (eg, hypertension, intrauterine growth restriction, and fetal distress).
- The management includes diet, exercise and insulin.



# Diet

- Low-carbohydrate diet , high fibre with caloric restriction
- Frequent small snacks may be needed between meals
- Avoid starvation



# Exercise

- Experts recommend that women with GDM should exercise regularly to control blood glucose levels.
- but an improvement in clinical outcomes has not been demonstrated from compliance with this recommendation.

# Insulin therapy

- Traditionally, insulin is used if dietary management does not maintain blood glucose at normal levels.
- Insulin may be initiated at 0.7 U/kg actual body weight/d given in divided dosages: two-thirds of the daily dosage before breakfast and the remainder of the dosage before dinner.
- Insulin therapy require close monitoring and adjustment based on blood glucose levels, meal choices, and activity levels.

# Insulin

- 3 pre-meal short acting insulin (actrapid) +/- intermediate-acting insulin (protophane) as it allows maximum flexibility
- Target blood glucose:
  - fasting < 5mmol/L
  - 2 hr <7 mmol/L



# Oral Hypoglycemic agents

- Implicated as teratogenic in animal studies esp first generation sulfonyureas
- In humans, scattered case reports of congenital abnormality
- Risk of congenital abnormality related to maternal glycemic control rather than mode of the anti-DM agents



# Oral agents

- Biguanides ( metformin)
- Cat B drug
- Commonly used in Polycystic Ovarian Disease (PCOD) to treat insulin resistance and normalize reproductive function
- Not teratogenic
- Reduce first trimester miscarriage



# Oral hypoglycemic agents

## Sulfonylureas

- 1<sup>st</sup> generation drug increase risk of neonatal hypoglycemia
- 2<sup>nd</sup> generation drug (Glyburide) no such effect and other morbidities .
- Cat C drug
- 4%-20% patients failed to achieve glucose control with maximum dose of drug
- Increase risk of preeclampsia and need for phototherapy



# Insulin Analogues

- 1. rapid-acting insulin analogs  
(lispro) Cat B

majority of evidence showed that it does not cross placenta, and has no adverse maternal or fetal effects





# Insulin Analogues

2. Long acting analogs  
glargine

Cat C drug

Not well studied systemically



# Monitoring

- Regular home glucose monitoring
- Insulin may be need to be adjusted as gestation advances
- HbA1c monitoring
- Fetal monitoring with USG
- Refer ophthalmologist



# Delivery

- Timing and mode of delivery individualised
- Intrapartum insulin infusion with glucose monitoring
- no contraindication for Breast feeding either with insulin or oral hypoglycemic agents



# Obstetrics management

- The goal of intrapartum GDM management is to avoid operative delivery, shoulder dystocia, birth trauma, and neonatal hypoglycemia.
- For patients who have maintained excellent control of blood glucose levels with diet and exercise, delivery is recommended at 40 weeks.
- For patients with medication-requiring GDM, induction at 38 to 39 weeks' gestation is recommended

# Obstetrics management

- In general, women with gestational diabetes who do not require insulin seldom require early delivery or other interventions.
- Elective cesarean delivery to avoid brachial plexus injuries in macrosomic infants is an important issue.

# Postpartum management

- In most women with GDM, hyperglycemia rapidly resolves shortly after delivery.
- It is reasonable to measure a single random or fasting blood glucose level before discharge from the hospital.

# Postpartum management

- Postpartum glucose tolerance testing is important for women who had GDM.
- Women with GDM have a 7-fold increased risk of developing type 2 diabetes mellitus compared with those who had a normoglycemic pregnancy.
- At 6 to 12 weeks postpartum, only one-third of women with persistent glucose intolerance have an abnormal fasting blood glucose level.
- Therefore, to detect all women with glucose intolerance, a 75-g, fasting, 2-hour, oral glucose tolerance test is recommended.